



Species search function 37



chain nodes :

11 12

ring nodes :

1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18 19 20 21

chain bonds :

8-11 9-12 12-21

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 13-19 14-15
14-21 15-16 16-17 17-18 19-20 20-21

exact/norm bonds :

5-7 6-10 7-8 8-9 8-11 9-10 13-19 14-21 19-20 20-21

exact bonds :

9-12 12-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom

LOGINID:sssptal611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	28	Oct 21	EVENTLINE has been reloaded
NEWS	29	Oct 24	BEILSTEIN adds new search fields
NEWS	30	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	31	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	32	Nov 18	DKILIT has been renamed APOLLIT
NEWS	33	Nov 25	More calculated properties added to REGISTRY
NEWS	34	Dec 02	TIBKAT will be removed from STN
NEWS	35	Dec 04	CSA files on STN
NEWS	36	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	37	Dec 17	TOXCENTER enhanced with additional content
NEWS	38	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS EXPRESS			October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:21:20 ON 18 DEC 2002

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:21:28 ON 18 DEC 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 DEC 2002 HIGHEST RN 476608-54-5

DICTIONARY FILE UPDATES: 17 DEC 2002 HIGHEST RN 476608-54-5

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09585925.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 16:21:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 264 TO ITERATE

100.0% PROCESSED 264 ITERATIONS 105 ANSWERS
SEARCH TIME: 00.00.01

L2 105 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	140.28	140.49

FILE 'CAPLUS' ENTERED AT 16:21:56 ON 18 DEC 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Dec 2002 VOL 137 ISS 25
FILE LAST UPDATED: 17 Dec 2002 (20021217/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

12/18/2002

09585925.trn


=> s l2

L3 1 L2


=> d abs ibib hitstr 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB Title compds. [I; Q = N, CR2; X = S, O, NOR3; Y = S, O, SO, SO2; R, R1 independently = H, aliph., aryl, heterocyclyl; R2 = H, CH3; R3 = H, COR4; R4 = alkyl, alkenyl, alkynyl, aryl; n = 0, 1; R5 = 7-Cl, 7-CH3, 6-CF3, 6-CH3, 6-Cl, 7-OCH3, 6-CH3CONH, 7-OH, etc.] are prepd. Title compds. and physiol. acceptable salts are inhibitors of receptor tyrosine kinase or non-receptor tyrosine kinase activity which involve in angiogenic process. Thus, title compds. can ameliorate disease states where angiogenesis or endothelial cell hyperproliferation is a factor and can be used to treat cancer and hyperproliferative disorders. Title compd. II was prepd.

ACCESSION NUMBER: 2000:881149 CAPLUS

DOCUMENT NUMBER: 134:42147

TITLE: Preparation and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors

INVENTOR(S): Rafferty, Paul; Calderwood, David; Arnold, Lee D.; Gonzalez Pascual, Beatriz; Ortego Martinez, Jose L.; Perez de Vega, Maria J.; Fernandez, Isabel F.

PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 183 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000075139	A2	20001214	WO 2000-US15324	20000602
WO 2000075139	A3	20010329		

W: AU, BG, BR, CA, CN, CZ, HR, HU, ID, IL, IN, JP, KR, MX, NO, NZ,
 PL, RU, SG, SK, TR, UA, US, ZA
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
 PT, SE

EP 1181282 A2 20020227 EP 2000-936476 20000602

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI

BR 2000011063 A 20020416 BR 2000-11063 20000602

NO 2001005899 A 20020130 NO 2001-5899 20011203

PRIORITY APPLN. INFO.:

US 1999-137410P P 19990603

WO 2000-US15324 W 20000602

OTHER SOURCE(S): MARPAT 134:42147


IT 312970-49-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)

RN 312970-49-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(4-hydroxybutyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



IT 312970-40-4P 312970-41-5P 312970-42-6P
 312970-43-7P 312970-44-8P 312970-45-9P
 312970-46-0P 312970-47-1P 312970-48-2P
 312970-50-6P 312970-51-7P 312970-52-8P
 312970-53-9P 312970-54-0P 312970-55-1P
 312970-56-2P 312970-57-3P 312970-58-4P
 312970-59-5P 312970-60-8P 312970-61-9P
 312970-62-0P 312970-63-1P 312970-64-2P
 312970-65-3P 312970-66-4P 312970-67-5P
 312970-68-6P 312970-69-7P 312970-70-0P
 312970-71-1P 312970-72-2P 312970-73-3P
 312970-74-4P 312970-75-5P 312970-76-6P
 312970-77-7P 312970-78-8P 312970-79-9P
 312970-80-2P 312970-81-3P 312970-82-4P
 312970-83-5P 312970-84-6P 312970-85-7P
 312970-86-8P 312970-87-9P 312970-88-0P
 312970-89-1P 312970-90-4P 312970-91-5P
 312970-92-6P 312970-93-7P 312970-94-8P
 312970-95-9P 312970-96-0P 312970-97-1P
 312970-98-2P 312970-99-3P 312971-00-9P
 312971-01-0P 312971-02-1P 312971-03-2P
 312971-04-3P 312971-05-4P 312971-06-5P
 312971-07-6P 312971-08-7P 312971-09-8P
 312971-10-1P 312971-11-2P 312971-12-3P
 312971-13-4P 312971-14-5P 312971-15-6P


312971-16-7P 312971-17-8P 312971-18-9P
 312971-19-0P 312971-20-3P 312971-21-4P
 312971-22-5P 312971-23-6P 312971-24-7P
 312971-25-8P 312971-26-9P 312971-27-0P
 312971-28-1P 312971-29-2P 312971-30-5P
 312971-31-6P 312971-32-7P 312971-33-8P
 312971-34-9P 312972-91-1P 312972-95-5P
 312973-58-3P 312974-25-7P 312974-26-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and effects of benzothiazinones and benzoxazinones as protein kinase inhibitors)

RN 312970-40-4 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, (2Z)- (9CI)
 (CA INDEX NAME)

Double bond geometry as shown.




RN 312970-41-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 7-chloro-2-(1H-indol-3-ylmethylene)- (9CI)
 (CA INDEX NAME)




RN 312970-42-6 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-7-methyl- (9CI)
 (CA INDEX NAME)




RN 312970-43-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-6-methyl- (9CI)
(CA INDEX NAME)

RN 312970-44-8 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 6-chloro-2-(1H-indol-3-ylmethylene)- (9CI)
(CA INDEX NAME)

RN 312970-45-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-7-methoxy- (9CI)
(CA INDEX NAME)


RN 312970-46-0 CAPLUS

CN Acetamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-6-yl]- (9CI) (CA INDEX NAME)




RN 312970-47-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-7-nitro- (9CI)
(CA INDEX NAME)




RN 312970-48-2 CAPLUS

CN Acetamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)




RN 312970-50-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-51-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[(2-hydroxyethoxy)methyl]-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-52-8 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)propyl]-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-53-9 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-(1H-indol-3-ylmethylene)- (9CI)
 (CA INDEX NAME)




RN 312970-54-0 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 7-amino-2-(1H-indol-3-ylmethylene)- (9CI)
 (CA INDEX NAME)



RN 312970-55-1 CAPLUS
 CN Urea, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]-N'-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 312970-56-2 CAPLUS
 CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 312970-57-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(2-methyl-1H-indol-3-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 312970-58-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 7-hydroxy-2-[[6-[(2-hydroxyethoxy)methyl]-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-59-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-methyl-1H-indol-3-yl)methylene]-
(9CI) (CA INDEX NAME)




RN 312970-60-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(1-methylethyl)-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-61-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)-2-hydroxypropyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312970-62-0 CAPLUS

CN Benzamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-63-1 CAPLUS


CN Acetamide, 2-chloro-N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)



RN 312970-64-2 CAPLUS


CN 4-Morpholineacetamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-

1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)




RN 312970-65-3 CAPLUS

CN 2-Propenamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)




RN 312970-66-4 CAPLUS

CN 4-Morpholinepropanamide, N-[3,4-dihydro-2-(1H-indol-3-ylmethylene)-3-oxo-2H-1,4-benzothiazin-7-yl]- (9CI) (CA INDEX NAME)




RN 312970-67-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6-hydroxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-68-6 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312970-69-7 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-amino-2-methyl-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-70-0 CAPLUS
 CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 312970-71-1 CAPLUS
 CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)




RN 312970-72-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 312970-73-3 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312970-74-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6,7,8,9-tetrahydro-8-(hydroxymethyl)pyrido[1,2-a]indol-10-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312970-75-5 CAPLUS

CN 1H-Indole-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 312970-76-6 CAPLUS

CN 1H-Indole-4-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 312970-77-7 CAPLUS

CN 1H-Indole-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-.alpha.-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 312970-78-8 CAPLUS

CN 1H-Indole-7-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 312970-79-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 312970-80-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(1-cyclopentyl-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-81-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-(tetrahydro-3-furanyl)-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)




RN 312970-82-4 CAPLUS

CN 1H-Indole-6-sulfonamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 312970-83-5 CAPLUS

CN Acetamide, N-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-5-yl]methyl]- (9CI) (CA INDEX NAME)




RN 312970-84-6 CAPLUS

CN 1H-Indole-1-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 312970-85-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-(hydroxymethyl)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)



RN 312970-86-8 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(6-methoxy-1H-indol-3-yl)methylene]- (9CI) (CA INDEX NAME)



RN 312970-87-9 CAPLUS


CN 1H-Indole-6-carboxylic acid, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 2-(1-pyrrolidinyl)ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 312970-88-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1-methyl-, 2-(dimethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 312970-89-1 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-, 3-(dimethylamino)propyl ester (9CI) (CA INDEX NAME)



RN 312970-90-4 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1-(2-hydroxyethyl)-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 312970-91-5 CAPLUS


CN 1H-Indole-6-carboxamide, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-pyrrolidiny)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 312970-92-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 312970-93-7 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 312970-94-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 312970-95-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)



RN 312970-96-0 CAPLUS


CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 312970-97-1 CAPLUS


CN 1H-Indole-6-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-

ylidene)methyl]-N-[2-(dimethylamino)ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 312970-98-2 CAPLUS


CN Piperazine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-6-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 312970-99-3 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[2-(1-piperidinyl)ethoxy]-1H-indol-3-yl]methylene]-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 312971-00-9 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[3-(dimethylamino)propoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-01-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[2-(4-morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-02-1 CAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-5-[3-(dimethylamino)propoxy]-, 1-methylethyl ester (9CI) (CA INDEX NAME)




RN 312971-03-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[3-(dimethylamino)propoxy]-1-methyl-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-04-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-methyl-5-[2-(4-morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-05-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-06-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[5-[2-(dimethylamino)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-07-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[3-(dimethylamino)propoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-08-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(4-morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-09-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(1-piperidinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-10-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(1-pyrrolidinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-11-2 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(dimethylamino)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-12-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(dimethylamino)-2-methylpropoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-13-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-14-5 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[(1-methyl-3-piperidinyl)methoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-15-6 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[7-[(dimethylamino)methyl]-6-hydroxy-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-16-7 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[7-[(dimethylamino)methyl]-6-[2-(4-morpholinyl)ethoxy]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-17-8 CAPLUS

CN Urea, N-[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2-methyl-1H-indol-5-yl]-N'-ethyl- (9CI) (CA INDEX NAME)




RN 312971-18-9 CAPLUS

CN Benzenesulfonamide, N-[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-2-methyl-1H-indol-5-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 312971-19-0 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[[[3-(dimethylamino)propyl]amino]methyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-20-3 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[6-[[[2-methoxyethyl]amino]methyl]-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 312971-21-4 CAPLUS

CN 1H-Indole-1-acetic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312971-22-5 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 312971-23-6 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 312971-24-7 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 312971-25-8 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 312971-26-9 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 312971-27-0 CAPLUS

CN 1H-Indole-7-carboxamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 312971-28-1 CAPLUS

CN 1H-Indole-1-acetamide, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 312971-29-2 CAPLUS

CN 1H-Indole-1-acetamide, N,N-bis[2-(diethylamino)ethyl]-3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312971-30-5 CAPLUS

CN 1,4'-Bipiperidine, 1'--[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-1-yl]acetyl]- (9CI) (CA INDEX NAME)




RN 312971-31-6 CAPLUS

CN 1H-Indole-1-acetamide, N-[2-(diethylamino)ethyl]-3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 312971-32-7 CAPLUS

CN 1H-Indole-7-carboxylic acid, 3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]- (9CI) (CA INDEX NAME)




RN 312971-33-8 CAPLUS

CN Piperazine, 1-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-7-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 312971-34-9 CAPLUS

CN 1-Piperazineethanol, 4-[[3-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-2-ylidene)methyl]-1H-indol-7-yl]carbonyl]- (9CI) (CA INDEX NAME)




RN 312972-91-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 312972-95-5 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-, 1-oxide (9CI) (CA INDEX NAME)



RN 312973-58-3 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]methylene]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 312970-52-8
 CMF C22 H23 N3 O S




CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 312974-25-7 CAPLUS
 CN 2H-1,4-Benzothiazin-3(4H)-one, 2-(1H-indol-3-ylmethylene)-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 312974-26-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-hydroxy-1H-indol-3-yl)methylene]-
(9CI) (CA INDEX NAME)

IT 312973-44-7 312973-45-8


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. and effects of benzothiazinones and benzoxazinones as protein
kinase inhibitors)

RN 312973-44-7 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[(Z)-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-
2-ylidene)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 312973-45-8 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 2-[(5-hydroxy-1H-indol-3-yl)methylene]-,
(2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



12/18/2002

09585925.trn

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.79

145.28

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.62

-0.62

STN INTERNATIONAL LOGOFF AT 16:22:23 ON 18 DEC 2002